|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 29, 2017 ) According to Publisher, the Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth.
For more information about this report: http://www.reportsweb.com/haemoglobinopathies-global-market-outlook-2016-2022
Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth.
Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma.
Disorders Covered:
- Sickle Cell Disease
- Haemoglobin variants diseases
Haemoglobin C disease
Haemoglobin S-C disease
- Thalassemia
Drugs Covered:
- NiCord
- ZFP Transcription Factors
- ALN-TMP
- Drug Targeting PRMT5
- Drug Targeting Protein Arginine Methyltransferase 5
Diagnosis Covered:
- Genetic Testing
- Blood Testing
- Pre-implantation Genetic Diagnosis
- Prenatal Genetic Testing
- Haemoglobin Electrophoresis
Therapies Covered:
- Iron Chelation Therapy
- Blood Transfusion
- Hydroxyurea
- Bone Marrow Transplant
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001564879/sample
Regions Covered:
- North America
US
Canada
Mexico
- Europe
Germany
France
Italy
UK
Spain
Rest of Europe
- Asia Pacific
Japan
China
India
Australia
New Zealand
Rest of Asia Pacific
- Rest of the World
Middle East
Brazil
Argentina
South Africa
Egypt
What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Company Profiling
11.1 Gamida Cell
11.2 Alnylam Pharmaceuticals
11.3 Biogen Idec
11.4 Genetix Pharmaceuticals
11.5 Global Blood Therapeutics Inc.
11.6 Pfizer Inc.
11.7 Mast Therapeutics
11.8 Emmaus Life Sciences, Inc.
11.9 Prolong Pharmaceuticals
11.10 Celgene Corporation
11.11 HemaQuest Pharmaceuticals
11.12 Sangamo BioSciences Inc
11.13 Cancer Therapeutics CRC Pty Ltd
11.14 Datar Genetics Limited
11.15 Optinova Ab
11.16 Anthera Pharmaceuticals
11.17 AcceleronPharma
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001564879/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
